All In Biotech

Drug Trial Radar · NCT00011986

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer

A Phase III Randomized Trial Of Paclitaxel And Carboplatin Versus Triplet Or Sequential Doublet Combinations In Patients With Epithelial Ovarian Or Primary Peritoneal Carcinoma

Last checked: Nov 19, 2026Latest source record: Apr 16, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 4,312 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,312

Actual

Start

Jan 2001

Primary completion

Mar 2010

Study completion Jan 28, 2013

Sponsor

Lead sponsor
Gynecologic Oncology GroupResearch network
Sponsor type
Research network
Collaborators
SWOG Cancer Research Network; Medical Research Council; National Cancer Institute (NCI)
First posted
Jan 27, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is most effective in treating ovarian epithelial cancer and peritoneal cancer. Randomized phase III trial to compare the effectiveness of various combination chemotherapy regimens in treating patients who have stage III or stage IV ovarian cancer or primary peritoneal cancer.

Conditions

  • Primary Peritoneal Carcinoma
  • Stage III Ovarian Cancer
  • Stage IV Ovarian Cancer

Interventions

  • PaclitaxelDrug

    Given IV

  • CarboplatinDrug

    Given IV

  • Gemcitabine HydrochlorideDrug

    Given IV

  • Pegylated Liposomal Doxorubicin HydrochlorideDrug

  • Topotecan HydrochlorideDrug

    Given IV

  • Therapeutic Conventional SurgeryProcedure

    Undergo surgery

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: Up to 9 years
  2. Progression-free SurvivalTime frame: From the date of enrollment to first progression or death or last contact, if alive and progression free.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Gynecologic Oncology Group

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.